This approach minimizes the appetite rebound that can occur during a washout but may increase GI side effects during the first 2 weeks of retatrutide as both receptor systems are in flux
Overweight with High-Risk History: A BMI of 27 or greater, accompanied by a diagnosis of prediabetes, previous heart attack, previous stroke, or peripheral artery disease
Technical Specifications Compound: BPC-157 (Synthetic Pentadecapeptide) Format: Lyophilized peptide powder Strength: 10 mg per vial Purity: 9899% (COA included) Appearance: White lyophilized powder Category: Research peptide reagent Intended Use This product is intended strictly for: Laboratory experimentation In-vitro scientific research Biochemical and molecular studies Non-human preclinical model development Institutional or academic research programs Not intended for: Human or animal consumption Injection, ingestion, inhalation, or topical use Medical, therapeutic, diagnostic, or cosmetic purposes This compound is not approved by Health Canada, FDA, or any regulatory authority for clinical use
doi:10.1016/j.bbi.2012.01.006 [17] Endres D, Pollak TA, Bechter K, et al
This medication builds momentum gradually
Researchers primarily study this compound for its powerful effects on weight loss, metabolic health, and appetite control